Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy
Crossref DOI link: https://doi.org/10.1007/s40271-017-0229-9
Published Online: 2017-03-28
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rydén, Anna
Blackhall, Fiona
Kim, Hye Ryun
Pillai, Rathi N.
Braam, Lauren
Martin, Mona L.
Walding, Andrew
Funding for this research was provided by:
AstraZeneca Gothenburg, Mölndal, Sweden
License valid from 2017-03-28